Skip to main content
. Author manuscript; available in PMC: 2016 Dec 2.
Published in final edited form as: Brain Res. 2015 Oct 8;1628(0 0):254–264. doi: 10.1016/j.brainres.2015.09.033

Figure 6. Schematic of proposed aggregation pathway.

Figure 6

Polyglutamine-expanded AR entities that misfold early in the course of disease are distinguished by 3B5H10-immunoreactivity, lower densities, and larger sizes. Later-stage, insoluble aggregates display higher densities and smaller sizes, and are unable to bind 3B5H10. Whether slow-migrating polyglutamine-expanded AR species become fast-migrating polyglutamine-expanded AR species is under investigation.